The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.

The firm will evaluate the drug's safety and early efficacy in patients with advanced AKT1 E17K-mutant solid tumors.

Under Project Impact, one of four programs backed by $200 million in funds, researchers aim to harmonize EHR data and build an AI model to improve cancer care.

BioCardia wants to gauge whether it has enough evidence to pursue regulatory approval for CardiAMP in ischemic heart failure.

NEW YORK – Adaptimmune on Monday said it will sell three autologous T-cell receptor (TCR) T-cell therapies, including its approved treatment for synovial sarcoma Tecelra (afamitresgene autoleucel), to ...

NEW YORK – Strong uptake of AstraZeneca's Tagrisso (osimertinib) in the second quarter of 2025 and positive overall survival results from the Phase III FLAURA2 trial have bolstered the firm's ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

NEW YORK – Sarepta Therapeutics will resume shipping its gene therapy for Duchenne muscular dystrophy to sites treating ambulatory patients, the company announced Monday evening. The firm had paused ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...